ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (video)

Spreaker is getting a new look!

Preview our new listening experience personalized just for you.

ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (video)

GRACEcast

00:00

09:48

Like Download

Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive biomarkers ERCC1 and RRM1 in advanced NSCLC.

Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive biomarkers ERCC1 and RRM1 in advanced NSCLC. read more read less

10 years ago #2013, #asco, #cancergrace, #david, #dr, #edward, #ercc1, #garon, #geffen, #grace, #gracecast, #madeit, #medicine, #of, #rrm1, #school, #ucla

0 Comments

This episode has no messages yet. Be the first to write a message!

Spreaker is getting a new look!